[{"orgOrder":0,"company":"Aexon Labs","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"AEX-2","moa":"","graph1":"Sleep","graph2":"Preclinical","graph3":"Aexon Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"Aexon Labs \/ NLS Pharmaceutics","highestDevelopmentStatusID":"4","companyTruncated":"Aexon Labs \/ NLS Pharmaceutics"},{"orgOrder":0,"company":"Aexon Labs","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AEX-2","moa":"OX1\/2 receptor","graph1":"Sleep","graph2":"Preclinical","graph3":"Aexon Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Aexon Labs \/ Aexon Labs","highestDevelopmentStatusID":"4","companyTruncated":"Aexon Labs \/ Aexon Labs"}]

Find Clinical Drug Pipeline Developments & Deals by Aexon Labs

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ASPEN
                          Not Confirmed
                          ASPEN
                          Not Confirmed

                          Details : AEX-2 is a potential first-in-class non-sulfonamide dual orexin receptor agonist (DOXA), which is being evaluated for narcolepsy and related neurological disorders.

                          Product Name : AEX-2

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 27, 2025

                          Lead Product(s) : AEX-2

                          Therapeutic Area : Sleep

                          Highest Development Status : Preclinical

                          Recipient : NLS Pharmaceutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ASPEN
                          Not Confirmed
                          ASPEN
                          Not Confirmed

                          Details : The agreement grants NLS global rights to next-gen oral OX1R/OX2R agonists, including AEX-2, tailored for narcolepsy, idiopathic hypersomnia, Parkinson's disease, dementia with Lewy bodies.

                          Product Name : AEX-2

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 20, 2024

                          Lead Product(s) : AEX-2

                          Therapeutic Area : Sleep

                          Highest Development Status : Preclinical

                          Sponsor : NLS Pharmaceutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank